IP Verse

Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione

Patent No. EP2797581 (titled "Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione") was filed by Amgen Europe on Dec 26, 2012. The application was issued on May 6, 2020.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GALENICUM HEALTH SLUFeb 8, 2021GALENICUM HEALTH SLU
KRKAFeb 5, 2021HOEFER & PARTNER PATENTANWALTE MBB
GENERICS UKJan 19, 2021ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2797581

AMGEN EUROPE
Application Number
EP12808662A
Filing Date
Dec 26, 2012
Status
Revoked
Aug 27, 2021
Publication Date
May 6, 2020
External Links
Slate, Register , Google Patents